Nurix inks deal with Seagen on cancer therapeutics

8 September 2023
nurix-logo

US clinical-stage biopharma Nurix Therapeutics (Nasdaq: NRIX) saw its shares rise almost 11% to $9.19 yesterday morning, after it announced a multi-year, multi-target strategic collaboration agreement with Seagen (Nasdaq: SEGN) to advance a new class of medicines called degrader-antibody conjugates (DACs) for use in cancer.

The collaboration will focus on an innovative approach to combine two powerful technologies to target cancer - antibody-drug conjugation (ADC) and targeted protein degradation (TPD) - with the goal of creating drugs with new mechanisms of action as well as improved specificity and anti-cancer activity.

Financial and other terms of the accord

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Biotechnology